Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis

AIM: The Certolizumab–Optimal Prevention of joint damage for Early Rheumatoid Arthritis (C‐OPERA) study demonstrated that in methotrexate (MTX)‐naïve early RA patients with poor prognostic factors, 1‐year certolizumab pegol (CZP) therapy added to the first year of 2‐year optimized MTX therapy brings...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Rheum Dis
Main Authors: Tanaka, Yoshiya, Atsumi, Tatsuya, Yamamoto, Kazuhiko, Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Eguchi, Katsumi, Watanabe, Akira, Origasa, Hideki, Shoji, Toshiharu, Miyasaka, Nobuyuki, Koike, Takao
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065202/
https://ncbi.nlm.nih.gov/pubmed/31957303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1756-185X.13780
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados